37,425 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 37,425 shares of the company’s stock, valued at approximately $311,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in shares of Amneal Pharmaceuticals by 20.7% during the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock valued at $4,771,000 after buying an additional 128,772 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock worth $5,148,000 after acquiring an additional 710,598 shares during the period. Jackson Creek Investment Advisors LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $1,027,000. Nisa Investment Advisors LLC increased its position in shares of Amneal Pharmaceuticals by 3,279.8% during the second quarter. Nisa Investment Advisors LLC now owns 228,917 shares of the company’s stock valued at $1,454,000 after purchasing an additional 222,144 shares during the period. Finally, Rubric Capital Management LP raised its stake in shares of Amneal Pharmaceuticals by 12.4% in the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after purchasing an additional 1,179,830 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Insider Activity at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Trading Up 4.1 %

NASDAQ AMRX opened at $8.07 on Wednesday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a 50 day moving average of $8.47 and a 200-day moving average of $7.92. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -11.87 and a beta of 1.12.

Analyst Upgrades and Downgrades

AMRX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Piper Sandler upped their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.